HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

UFT plus calcium folinate plus radiotherapy for recurrent rectal cancer.

Abstract
Uracil and tegafur (in a molar ratio of 4:1 [UFT]) plus calcium folinate comprise the components of the oral agent, Orzel, which appears to have activity comparable to intravenously administered 5-fluorouracil. This article describes the design of an open-label, disease-oriented, phase I trial of UFT plus calcium folinate in combination with simultaneous pelvic radiation for recurrent rectal cancer. This trial is designed to determine the maximum tolerated dose and dose-limiting toxicity of this regimen.
AuthorsW Hoffmann, M Schiebe, J Dethling, C Martin
JournalOncology (Williston Park, N.Y.) (Oncology (Williston Park)) Vol. 13 Issue 7 Suppl 3 Pg. 125-6 (Jul 1999) ISSN: 0890-9091 [Print] United States
PMID10442380 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial)
Chemical References
  • Tegafur
  • Uracil
  • Leucovorin
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Follow-Up Studies
  • Humans
  • Leucovorin (therapeutic use)
  • Neoplasm Recurrence, Local
  • Radiotherapy, Adjuvant
  • Rectal Neoplasms (drug therapy, radiotherapy)
  • Safety
  • Tegafur (therapeutic use)
  • Treatment Outcome
  • Uracil (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: